Research advances in immunopathogenesis and targeted therapeutic strategies for primary biliary cholangitis comorbid with Sjögren’s syndrome
- VernacularTitle:原发性胆汁性胆管炎合并干燥综合征的免疫机制及靶向治疗研究进展
- Author:
Xiaoying DONG
1
;
Yongzhen ZHAI
1
Author Information
- Publication Type:Review
- Keywords: Primary Biliary Cholangitis; Sjögren’s Syndrome; Immunomodulation; Molecular Targeted Therapy
- From: Journal of Clinical Hepatology 2025;41(6):1181-1187
- CountryChina
- Language:Chinese
- Abstract: Primary biliary cholangitis （PBC） and Sjögren’s syndrome （SS） are both autoimmune disorders characterized by the involvement of epithelial tissue， and comorbidity of PBC and SS is often observed in clinical practice， suggesting that these two diseases may have common pathogeneses. Currently， there are still no specific targeted therapies for PBC and SS， and the therapeutic approach for systemic manifestations mainly relies on the treatment regimens for other autoimmune disorders. This article reviews the various potential therapeutic targets that have been clarified in the pathogenesis of PBC and SS and points out that targeted therapies for these two diseases can be developed based on the common immunopathological mechanism of PBC and SS， thereby providing valuable ideas for developing novel therapies.
